Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Neumora Therapeutics, Inc. (NMRA)

Neumora names Joshua Pinto CEO; Q2 net loss narrows to $43.1 million

Positive Impact 4 of 5 leadership Written later

Neumora reported a second-quarter 2026 net loss of $43.1 million, down from $52.7 million a year earlier, as research and development and general and administrative expenses declined. On the same day, President Joshua Pinto became chief executive officer effective August 14, 2026, succeeding Paul L. Berns, who becomes Executive Chairperson. The company said its $116.8 million in cash and cash equivalents is expected to support operations into the third quarter of 2027.

Key points

  • Q2 2026 net loss was $43.1 million, compared with $52.7 million in Q2 2025.
  • R&D expense was $29.3 million (Q2 2025: $38.7 million); G&A expense was $12.9 million (Q2 2025: $15.3 million).
  • Joshua Pinto, Ph.D., succeeds Paul L. Berns as CEO effective August 14, 2026, and was appointed a Class III director.
  • Cash and cash equivalents were $116.8 million as of June 30, 2026, expected to fund operations into the third quarter of 2027.

The filing

CompanyNeumora Therapeutics, Inc. (NMRA)
Form8-K, current report
Filed with the SECAug 14, 2026, 7:13 AM ET
Accession number0001193125-26-350349

Items reported: 2.02 Results of Operations5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 14, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.